key: cord-0079038-4i7kb1xu
authors: Ho, Jonathan D.; McNish, Alicia; McDonald, Letisha; Burrell, Carol; Smith-Matthews, Stephanie
title: Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
date: 2022-05-10
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2022.05.002
sha: a90ca2c0c9cfc7a8ded425622c8b3d85ae96259a
doc_id: 79038
cord_uid: 4i7kb1xu

nan

Recently, there have been rare reports detailing the onset or recurrence of alopecia areata (AA) after vaccination against COVID-19. [1] [2] [3] We report the onset of alopecia universalis (AU) in a 51-year-old woman occurring within one week of vaccination with ChAdOx1 nCoV-19 vaccine (AZD1222). A combination of typical findings and uncommon/atypical pathologic findings were identified.

A 51-year-old Afro-Caribbean woman with no chronic illnesses presented to the dermatology clinic with new-onset alopecia (Fig 1) involving her scalp, eyebrows/lashes, axillae, limbs, and pubic area after vaccination with ChAdOx1 nCoV-19 vaccine (AZD1222; AstraZeneca, University of Oxford). She started no new medications and received no other vaccines around this time. Before presentation, she had thick hair, denied a personal/family history of alopecia, autoimmune connective tissue or thyroid disease, and was not on medications. Intense scalp pruritus occurred 3 days after vaccination with rapid loss of scalp hair, leading to near-complete baldness within 3 weeks, except for a retained occipital patch. She received her second dose 8 weeks later and lost the remaining patch within 1 week. Pruritus and burning involving the eyebrows and eyelashes developed with accompanying loss of hair. Axillary, pubic, and limb alopecia was also noted. She sought dermatologic care. A scalp biopsy and blood work were performed (approximately 10 weeks after initial hair loss).

Transverse histologic sections revealed peribulbar lymphocytic inflammation, retained sebaceous glands, pigment in fibrous tracts, approximately 30% of hairs in catagen/telogen phase, follicular structures failing to form hair, nanogen and dystrophic hairs, empty infundibulae, profound miniaturization with small caliber hairs, and a terminal:vellus ratio of \1:1 (Fig 2, A-F ). Although these changes were typical of AA/AU, other unusual findings were noted (Fig 3, Table I ). The infiltrate was dense and mixed in nature with lymphocytes, numerous plasma cells (predominating in sections), eosinophils, and neutrophils. Inflammation involved the peribulbar, isthmic, and infundibular portions of the follicle. Intrafollicular neutrophils were present in multiple miniaturized follicles. Focal concentric perifollicular fibrosis, follicular destruction with associated multinucleated giant cells, and naked hair shafts were identified (Fig 3, A-D) . Periodic acideSchiff staining was negative for fungi. No perieccrine inflammation was present. Thyroidestimulating hormone and complete blood cell count were normal. Antithyroid peroxidase and antithyroglobulin antibodies as well as enzyme-linked immunosorbent assay analysis for antinuclear antibodies and serology for syphilis were negative. The patient was referred to us for additional input.

Examination revealed extensive scalp alopecia. No scarring, scale, pustules, or erythema was noted. Significant loss of eyebrows, eyelashes, axillary, and pubic hair were noted. Limb hair was present, but the patient reported a follicular density markedly lower than baseline (Fig 1, A-D) . Dermatoscopy revealed broken hairs, yellow dots, and occasional exclamation mark hairs (Fig 1, E and F ) . Given the physical examination, dermatoscopic and some histopathologic features, a diagnosis of AU with additional unusual/uncommon microscopic findings was rendered. The patient commenced clobetasol propionate ointment under occlusion and intralesional triamcinolone acetonide 10 mg/mL (2 sessions, 4 weeks apart) while awaiting approval for oral tofacitinib. At the time of writing, she had areas of sparse white regrowth and loss of exclamation mark hairs.

Reports of hair loss following vaccination against COVID-19 are mounting. 1-4 A total of 226 cases of AA or variants thereof have been logged in association with COVID-19 vaccination in the Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System database. 4 Although these are unverified and do not indicate causality or accurate classification, increasing reports in the published literature suggest potential association. A review of articles in the PubMed/MEDLINE database revealed 3 articles (13 patients). 1-3 While most cases were associated with BioNTech Pfizer and Moderna vaccines, 3 3 cases developing after vaccination with AZD1222 have been documented. 1,2 Additionally, most patients had preexisting AA or autoimmune thyroid disease. 1-3 Patchy disease (some extensive) was most common, but 1 patient with alopecia totalis and 2 with AU have been described (Pfizer/ Moderna). 3 Our patient presented with AU beginning within the week of vaccination. Despite some retained hair, complete scalp alopecia and significant loss of body hair makes AU the best designation. She had no personal or family history of autoimmunity, thyroid disease, or alopecia. Although striking, intense pruritus prior to onset of hair loss is occasionally seen in AA and may be associated with the marked inflammation. 5 Biopsy demonstrated a combination of typical AA/AU findings in conjunction with unusual/uncommon features (Figs 2 and 3 , Table I ).

In particular, the density and mixed nature of the infiltrate, perifollicular fibrosis, follicular destruction, and intrafollicular neutrophils are unusual/uncommon in AA/AU. 6, 7 Although plasma cells and eosinophils may be seen, 6,8 the density and presence at all levels of the follicle, rather than the classic peribulbar lymphocytic ''swarm of bees'' is atypical. Perhaps heavier inflammation correlates with the acute nature of the disease. 6-9 Intrafollicular neutrophils are not typical of AA, and perifollicular fibrosis with follicular destruction is rare, being more common in scarring alopecias. 6-10 Collision with incidental acute folliculitis was considered and cannot be entirely excluded. However, both the patient and dermatologist denied a compatible history/examination, and intrafollicular neutrophils were observed in multiple vellus follicles in the superior isthmus-toinfundibular sections. Follicular destruction, neutrophils, and perifollicular fibrosis also raised the possibility of a folliculitis decalvans. 10 Rapid onset, absence of pustules and tufting, retained sebaceous glands, and the dermatoscopic, clinical, and other pathologic features of AA excluded this entity. None of the existing reports of COVID-19 vaccine-related AA detail histopathologic findings. Potentially, these exuberant findings are characteristic of vaccinerelated AA. Additional cases with biopsy findings are necessary to determine homogeneity.

How vaccination may induce AA is unclear. AZD1222 uses a modified chimpanzee adenovirus to insert spike proteineencoding DNA into the host cell. Conversion to messenger RNA and resultant protein assembly allows production of the SARS-CoV-2 spike protein against which the host generates a T cell and antibody response. 1 Potentially, similarities between viral spike protein and hair proteins result in antibody cross-reactivity via molecular mimicry. 1 Further work elucidating the genesis of vaccine-associated autoimmunity is needed.

Although causality cannot be established, the sudden onset after vaccination, further complete loss after second exposure, lack of known autoimmune disease, and the increasing reports of this phenomenon suggest vaccination against COVID-19 may trigger/exacerbate AA.

Vaccines are invaluable in the fight against COVID-19. Patients with a history of AA or autoimmunity should be alerted as to the potential risk of exacerbation. This case may suggest a true association between vaccination and onset of AA/variants. Our case revealed unusual/uncommon histopathologic findings. Perhaps these features will be found to be characteristic of vaccine-related AA. Continued reporting of this phenomenon is required to further our understanding of this disease association.

None disclosed. 

Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/As-traZeneca): a potential triggering factor?

Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy

Alopecia areata after SARS-CoV-2 vaccination

Public Health Service (PHS), Centers for Disease Control (CDC)/Food and Drug Administration (FDA). The Vaccine Adverse Event Reporting System (VAERS) 1990 -01/14/2022, CDC WONDER On-line Database

Clinical and histopathological features of itch in patients with alopecia areata

Histopathologic features of alopecia areata: a new look

A comparison of vertical and transverse sections in the histological diagnosis of alopecia areata scalp biopsy specimens

Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata

Histologic features of alopecia areata other than peribulbar lymphocytic infiltrates

Primary cicatricial alopecia: other lymphocytic primary cicatricial alopecias and neutrophilic and mixed primary cicatricial alopecias